Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 21;7(7):e2299.
doi: 10.1038/cddis.2016.211.

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response

C Botta  1 , G Misso  2 , E C Martino  3 , L Pirtoli  3 , M G Cusi  4 , P Tassone  1 , P Tagliaferri  1 , M Caraglia  2 , P Correale  3
Affiliations
Free PMC article

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response

C Botta et al. Cell Death Dis. .
Free PMC article
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the main bevacizumab-mediated immunomodulatory events. VEGF-A inhibition by bevacizumab has been correlated with a number of immunological events. Bevacizumab is able to promote DCs maturation, as well as to improve DCs' amount and function. In addition, this monoclonal antibody can improve both CD8+ CTLs and CD4+ T helper 1 cells (Th1) immune response in tumor surveillance. In addition, as part of the immunomodulatory events induced by VEGFA neutralization, bevacizumab leads to a significant inhibition of MDSCs and TAM accumulation in tumor microenvironment. Finally, the expression levels of several proangiogenic and proinflammatory factors appear strongly reduced upon bevacizumab treatment. CTLs, cytotoxic T cells; DCs, dendritic cells; MDSCs, myeloid-derived suppressor cells; TAM, tumor-associated macrophages; VEGF-A, vascular endothelial growth factor A
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Botta C et al Front Oncol 2014; 4: 348. - PMC - PubMed
    1. Hanahan D, Weinberg RA Cell 2011; 144: 646–674. - PubMed
    1. Correale P et al Clin Cancer Res 2012; 18: 850–857. - PubMed
    1. Correale P et al Oncoimmunology 2012; 1: 531–532. - PMC - PubMed
    1. Correale P et al J Immunother 2010; 33: 435–441. - PMC - PubMed

LinkOut - more resources